Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Spotlight Back On Indian Rotavirus Vaccine Controversy

Executive Summary

A public interest litigation (PIL) has sought to revive efforts to access segregated trial data from an indigenous oral rotavirus vaccine (Rotavac) in India amid concerns that it might be associated with a higher risk of intussusception in certain pockets of the country. And in a further dimension, an expert panel recently brought up a "representation" on the inclusion of intussusception in the vaccine's package insert.

You may also be interested in...



Indian Court Dismisses "Misconceived" PIL On Rotavirus Vaccine

An Indian court has dismissed a petition seeking complete trial data pertaining to an indigenous oral rotavirus vaccine (Rotavac) developed through a unique public-private partnership, noting that it is "misconceived" and "motivated with private interest".

India's rotavirus vaccine row: show me the data

A public interest litigation (PIL) has brought to the fore a simmering controversy over alleged safety signals concerning an indigenous oral rotavirus vaccine (Rotavac) developed through a unique public-private partnership in India.

Asia Deal Watch: China Grand, ETheRNA Create mRNA Vaccine JV

Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.

Topics

UsernamePublicRestriction

Register

LL1134940

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel